Epigenetic inactivation of DNA repair in breast cancer

Cancer Letters

Volumn 342, Issue 2, 2014, Pages 213-222

  Nowsheen, Somaira ^a   Aziz, Khaled ^b   Tran, Phuoc T ^b   Gorgoulis, Vassilis G ^c   Yang, Eddy S ^a   Georgakilas, Alexandros G ^d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Biomarkers; Breast cancer; Cancer; Carcinogenesis; DNA damage; Epigenetics; Personalized treatment

Indexed keywords

4SC 202; AZACITIDINE; DNA; ENTINOSTAT; HISTONE DEACETYLASE INHIBITOR; HYDRALAZINE; MICRORNA; SULFORAPHANE; TAMOXIFEN; UNCLASSIFIED DRUG; VALPROATE MAGNESIUM; VALPROIC ACID;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER PROGNOSIS; CANCER SCREENING; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL (TOPIC); DNA METHYLATION; DNA REPAIR; EARLY DIAGNOSIS; EPIGENETICS; GENE EXPRESSION; GENE INACTIVATION; HISTONE ACETYLATION; HISTONE MODIFICATION; HUMAN; LEUKEMIA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MOLECULAR INTERACTION; MYELOMA; OUTCOME ASSESSMENT; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; SHORT SURVEY; SOLID TUMOR; TRIPLE NEGATIVE BREAST CANCER; UTERINE CERVIX CANCER;

EID: 84888199628     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.05.015     Document Type: Review

References (97)

1. Franco R., Schoneveld O., Georgakilas A.G., Panayiotidis M.I. Oxidative stress, DNA methylation and carcinogenesis. Cancer Lett. 2008, 266:6-12.
2. Vogelstein B., Kinzler K.W. The multistep nature of cancer. Trends Genet. 1993, 9:138-141.
3. Nigro J.M., Baker S.J., Preisinger A.C., Jessup J.M., Hosteller R., Cleary K., Signer S.H., Davidson N., Baylin S., Devilee P., Glover T., Collins F.S., Weslon A., Modali R., Harris C.C., Vogelstein B. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989, 342:705-708.
4. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. P53 mutations in human cancers. Science 1991, 253:49-53.
5. Berger A.H., Knudson A.G., Pandolfi P.P. A continuum model for tumour suppression. Nature 2011, 476:163-169.
6. Hutchinson E. Alfred Knudson and his two-hit hypothesis. Lancet Oncol. 2001, 2:642-645.
7. Jones P.A., Laird P.W. Cancer-epigenetics comes of age. Nat. Genet. 1999, 21:163-167.
8. Berger S.L., Kouzarides T., Shiekhattar R., Shilatifard A. An operational definition of epigenetics. Genes Dev. 2009, 23:781-783.
9. Sharma S., Kelly T.K., Jones P.A. Epigenetics in cancer. Carcinogenesis 2010, 31:27-36.
10. Cedar H., Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat. Rev. Genet. 2009, 10:295-304.
11. Fullgrabe J., Kavanagh E., Joseph B. Histone onco-modifications. Oncogene 2011, 30:3391-3403.
12. Allis C.D., Berger S.L., Cote J., Dent S., Jenuwien T., Kouzarides T. New nomenclature for chromatin-modifying enzymes. Cell 2007, 131:633-636.
13. Fullgrabe J., Hajji N., Joseph B. Cracking the death code: apoptosis-related histone modifications. Cell Death Differ. 2010, 17:1238-1243.
14. Rundlett S.E., Carmen A.A., Suka N., Turner B.M., Grunstein M. Transcriptional repression by UME6 involves deacetylation of lysine 5 of histone H4 by RPD3. Nature 1998, 392:831-835.
15. Vogelauer M., Wu J., Suka N., Grunstein M. Global histone acetylation and deacetylation in yeast. Nature 2000, 408:495-498.
16. Strahl B.D., Allis C.D. The language of covalent histone modifications. Nature 2000, 403:41-45.
17. Turner B.M. Histone acetylation and an epigenetic code. BioEssays 2000, 22:836-845.
18. Jenuwein T., Allis C.D. Translating the histone code. Science 2001, 293:1074-1080.
19. Robertson K.D. DNA methylation and chromatin - unraveling the tangled web. Oncogene 2002, 21:5361-5379.
20. Das P.M., Singal R. DNA methylation and cancer. J. Clin. Oncol. 2004, 22:4632-4642.
21. Baylin S.B., Esteller M., Rountree M.R., Bachman K.E., Schuebel K., Herman J.G. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum. Mol. Genet. 2001, 10:687-692.
22. Feinberg A.P., Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983, 301:89-92.
23. Robertson K.D. DNA methylation and human disease. Nat. Rev. Genet. 2005, 6:597-610.
24. Baylin S.B., Ohm J.E. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction?. Nat. Rev. Cancer 2006, 6:107-116.
25. Sproul D., Gilbert N., Bickmore W.A. The role of chromatin structure in regulating the expression of clustered genes. Nat. Rev. Genet. 2005, 6:775-781.
26. Ziech D., Franco R., Pappa A., Malamou-Mitsi V., Georgakila S., Georgakilas A.G., Panayiotidis M.I. The role of epigenetics in environmental and occupational carcinogenesis. Chem. Biol. Interact. 2010, 188:334-339.
27. Peters A.H.F.M., O'Carroll D., Scherthan H., Mechtler K., Sauer S., Schöfer C., Weipoltshammer K., Pagani M., Lachner M., Kohlmaier A., Opravil S., Doyle M., Sibilia M., Jenuwein T. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell 2001, 107:323-337.
28. S. Nowsheen, A.C. Whitley, and E.S. Yang, Biomarkers to assess the targeting of DNA repair pathways to augment tumor response to therapy. Curr. Mol. Med. 6 (2012). PMID: 22292444.
29. Gerson S.L. MGMT: its role in cancer aetiology and cancer therapeutics. Nat. Rev. Cancer 2004, 4:296-307.
30. Hegi M.E., Diserens A.-C., Gorlia T., Hamou M.-F., de Tribolet N., Weller M., Kros J.M., Hainfellner J.A., Mason W., Mariani L., Bromberg J.E.C., Hau P., Mirimanoff R.O., Cairncross J.G., Janzer R.C., Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005, 352:997-1003.
31. Hegi M.E., Liu L., Herman J.G., Stupp R., Wick W., Weller M., Mehta M.P., Gilbert M.R. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J. Clin. Oncol. 2008, 26:4189-4199.
32. Boks M.P., Derks E.M., Weisenberger D.J., Strengman E., Janson E., Sommer I.E., Kahn R.S., Ophoff R.A. The relationship of DNA methylation with age, gender and genotype in twins and healthy controls. PLoS ONE 2009, 4:e6767.
33. Teschendorff A.E., Menon U., Gentry-Maharaj A., Ramus S.J., Weisenberger D.J., Shen H., Campan M., Noushmehr H., Bell C.G., Maxwell A.P., Savage D.A., Mueller-Holzner E., Marth C., Kocjan G., Gayther S.A., Jones A., Beck S., Wagner W., Laird P.W., Jacobs I.J., Widschwendter M. Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res. 2010.
34. Ghoshal K., Li X., Datta J., Bai S., Pogribny I., Pogribny M., Huang Y., Young D., Jacob S.T. A folate- and methyl-deficient diet alters the expression of DNA methyltransferases and methyl CpG binding proteins involved in epigenetic gene silencing in livers of F344 rats. J. Nutr. 2006, 136:1522-1527.
35. Arita A., Costa M. Epigenetics in metal carcinogenesis: nickel, arsenic, chromium and cadmium. Metallomics 2009, 1:222-228.
36. Ren X., McHale C.M., Skibola C.F., Smith A.H., Smith M.T., Zhang L. An emerging role for epigenetic dysregulation in arsenic toxicity and carcinogenesis. Environ. Health Perspect. 2011, 119:11-19.
37. Gu W., Roeder R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997, 90:595-606.
38. Ikenoue T., Inoki K., Zhao B., Guan K.-L. PTEN acetylation modulates its interaction with PDZ domain. Cancer Res. 2008, 68:6908-6912.
39. Yao X.H., Nyomba B.L. Hepatic insulin resistance induced by prenatal alcohol exposure is associated with reduced PTEN and TRB3 acetylation in adult rat offspring. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008, 2008:R1797-R1806.
40. Bhakat K.K., Izumi T., Yang S.-H., Hazra T.K., Mitra S. Role of acetylated human AP-endonuclease (APE1/Ref-1) in regulation of the parathyroid hormone gene. EMBO J. 2003, 22:6299-6309.
41. Hasselgren P.O. Ubiquitination, phosphorylation, and acetylation - triple threat in muscle wasting. J. Cell. Phys. 2007, 213:679-689.
42. Zilberman D., Coleman-Derr D., Ballinger T., Henikoff S. Histone H2A.Z and DNA methylation are mutually antagonistic chromatin marks. Nature 2008, 456:125-129.
43. Valdes-Mora F., Song J.Z., Statham A.L., Strbenac D., Robinson M.D., Nair S.S., Patterson K.I., Tremethick D.J., Stirzaker C., Clark S.J. Acetylation of H2A.Z is a key epigenetic modification associated with gene deregulation and epigenetic remodeling in cancer. Genome Res. 2012, 22:307-321.
44. Gorrini C., Squatrito M., Luise C., Syed N., Perna D., Wark L., Martinato F., Sardella D., Verrecchia A., Bennett S., Confalonieri S., Cesaroni M., Marchesi F., Gasco M., Scanziani E., Capra M., Mai S., Nuciforo P., Crook T., Lough J., Amati B. Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature 2007, 448:1063-1067.
45. Tang Y., Luo J., Zhang W., Gu W. Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol. Cell 2006, 24:827-839.
46. Ikura T., Tashiro S., Kakino A., Shima H., Jacob N., Amunugama R., Yoder K., Izumi S., Kuraoka I., Tanaka K., Kimura H., Ikura M., Nishikubo S., Ito T., Muto A., Miyagawa K., Takeda S., Fishel R., Igarashi K., Kamiya K. DNA damage-dependent acetylation and ubiquitination of H2AX enhances chromatin dynamics. Mol. Cell. Biol. 2007, 27:7028-7040.
47. Sun Y., Jiang X., Chen S., Fernandes N., Price B.D. A role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM. Proc. Natl. Acad. Sci. USA 2005, 102:13182-13187.
48. Xie W., Song C., Young N.L., Sperling A.S., Xu F., Sridharan R., Conway A.E., Garcia B.A., Plath K., Clark A.T., Grunstein M. Histone H3 lysine 56 acetylation is linked to the core transcriptional network in human embryonic stem cells. Mol. Cell 2009, 33:417-427.
49. Das C., Lucia M.S., Hansen K.C., Tyler J.K. CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature 2009, 459:113-117.
50. Wang Q., Mora-Jensen H., Weniger M.A., Perez-Galan P., Wolford C., Hai T., Ron D., Chen W., Trenkle W., Wiestner A., Ye Y. ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proc. Natl. Acad. Sci. USA 2009, 2200-2205.
51. Osley M.A. Regulation of histone H2A and H2B ubiquitylation. Brief Funct. Genom. Proteom. 2006, 5:179-189.
52. Mailand N., Bekker-Jensen S., Faustrup H., Melander F., Bartek J., Lukas C., Lukas J. RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins. Cell 2007, 131:887-900.
53. Huen M.S.Y., Grant R., Manke I., Minn K., Yu X., Yaffe M.B., Chen J. RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly. Cell 2007, 131:901-914.
54. Kao C.-F., Hillyer C., Tsukuda T., Henry K., Berger S., Osley M.A. Rad6 plays a role in transcriptional activation through ubiquitylation of histone H2B. Genes Dev. 2004, 18:184-195.
55. Turner S.D., Ricci A.R., Petropoulos H., Genereaux J., Skerjanc I.S., Brandl C.J. The E2 ubiquitin conjugase Rad6 Is required for the ArgR/Mcm1 repression of ARG1 transcription. Mol. Cell. Biol. 2002, 22:4011-4019.
56. Luijsterburg M.S., Goedhart J., Moser J., Kool H., Geverts B., Houtsmuller A.B., Mullenders L.H.F., Vermeulen W., van Driel R. Dynamic in vivo interaction of DDB2 E3 ubiquitin ligase with UV-damaged DNA is independent of damage-recognition protein XPC. J. Cell Sci. 2007, 120:2706-2716.
57. Nicassio F., Corrado N., Vissers J.H.A., Areces L.B., Bergink S., Marteijn J.A., Geverts B., Houtsmuller A.B., Vermeulen W., Di Fiore P.P., Citterio E. Human USP3 Is a chromatin modifier required for S phase progression and genome stability. Curr. Biol. 2007, 17:1972-1977.
58. Deng H., Bao X., Cai W., Blacketer M.J., Belmont A.S., Girton J., Johansen J., Johansen K.M. Ectopic histone H3S10 phosphorylation causes chromatin structure remodeling in Drosophila. Development 2008, 135:699-705.
59. Kollareddy M., Dzubak P., Zheleva D., Hajduch M. Aurora kinases: structure, functions and their association with cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008, 152:27-33.
60. Mosch K., Franz H., Soeroes S., Singh P.B., Fischle W. HP1 recruits activity-dependent neuroprotective protein to H3K9me3 marked pericentromeric heterochromatin for silencing of major satellite repeats. PLoS ONE 2011, 6:e15894.
61. Bonner W.M., Redon C.E., Dickey J.S., Nakamura A.J., Sedelnikova O.A., Solier S., Pommier Y. [gamma]-H2AX and cancer. Nat. Rev. Cancer 2008, 8:957-967.
62. Meltzer P.S. Cancer genomics: small RNAs with big impacts. Nature 2005, 435:745-746.
63. O'Donnell K.A., Wentzel E.A., Zeller K.I., Dang C.V., Mendell J.T. C-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005, 435:839-843.
64. Cimmino A., Calin G.A., Fabbri M., Iorio M.V., Ferracin M., Shimizu M., Wojcik S.E., Aqeilan R.I., Zupo S., Dono M., Rassenti L., Alder H., Volinia S., Liu C.-g., Kipps T.J., Negrini M., Croce C.M. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. USA 2005, 102:13944-13949.
65. Gabriely G., Wurdinger T., Kesari S., Esau C.C., Burchard J., Linsley P.S., Krichevsky A.M. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol. Cell. Biol. 2008, 28:5369-5380.
66. Frankel L.B., Christoffersen N.R., Jacobsen A., Lindow M., Krogh A., Lund A.H. Programmed cell death 4 (PDCD4) is an important functional target of the MicroRNA miR-21 in breast cancer cells. J. Biol. Chem. 2008, 283:1026-1033.
67. Garzon R., Liu S., Fabbri M., Liu Z., Heaphy C.E.A., Callegari E., Schwind S., Pang J., Yu J., Muthusamy N., Havelange V., Volinia S., Blum W., Rush L.J., Perrotti D., Andreeff M., Bloomfield C.D., Byrd J.C., Chan K., Wu L.-C., Croce C.M., Marcucci G. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 2009, 113:6411-6418.
68. Lippman Z., May B., Yordan C., Singer T., Martienssen R. Distinct mechanisms determine transposon inheritance and methylation via small interfering RNA and histone modification. PLoS Biol 2003, 1:e67.
69. Haakensen V., Lingjaerde O., Luders T., Riis M., Prat A., Troester M.A., Holmen M., Frantzen J., Romundstad L., Navjord D., Bukholm I., Johannesen T., Perou C., Ursin G., Kristensen V., Rorresen-Dale A., Helland A. Gene expression profiles of breast biopsies from healthy women identify a group with claudin0low features. BMC Med. Genom. 2011, 4.
70. Prat A., Perou C.M. Mammary development meets cancer genomics. Nat. Med. 2009, 15:842-844.
71. Lim E., Vaillant F., Wu D., Forrest N.C., Pal B., Hart A.H., Asselin-Labat M.-L., Gyorki D.E., Ward T., Partanen A., Feleppa F., Huschtscha L.I., Thorne H.J., Fox S.B., Yan M., French J.D., Brown M.A., Smyth G.K., Visvader J.E., Lindeman G.J. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat. Med. 2009, 15:907-913.
72. Prat A., Parker J., Karginova O., Fan C., Livasy C., Herschkowitz J., He X., Perou C. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010, 12.
73. Herschkowitz J., Simin K., Weigman V., Mikaelian I., Usary J., Hu Z., Rasmussen K., Jones L., Assefnia S., Chandrasekharan S., Backlund M., Yin Y., Khramtsov A., Bastein R., Quackenbush J., Glazer R., Brown P., Green J., Kopelovich L., Furth P., Palazzo J., Olopade O., Bernard P., Churchill G., Van Dyke T., Perou C. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007, 8:R76.
74. Hennessy B.T., Gonzalez-Angulo A.-M., Stemke-Hale K., Gilcrease M.Z., Krishnamurthy S., Lee J.-S., Fridlyand J., Sahin A., Agarwal R., Joy C., Liu W., Stivers D., Baggerly K., Carey M., Lluch A., Monteagudo C., He X., Weigman V., Fan C., Palazzo J., Hortobagyi G.N., Nolden L.K., Wang N.J., Valero V., Gray J.W., Perou C.M., Mills G.B. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009, 69:4116-4124.
75. Jackson S.P., Bartek J. The DNA-damage response in human biology and disease. Nature 2009, 461:1071-1078.
76. Bartek J., Lukas C., Lukas J. Checking on DNA damage in S phase. Nat. Rev. Mol. Cell Biol. 2004, 5:792-804.
77. Wang H., Yang E.S., Jiang J., Nowsheen S., Xia F. DNA damage-induced cytotoxicity is dissociated from BRCA1's DNA repair function but is dependent on its cytosolic accumulation. Cancer Res. 2010, 70:6258-6267.
78. Jiang J., Yang E.S., Jiang G., Nowsheen S., Wang H., Wang T., Wang Y., Billheimer D., Chakravarthy A.B., Brown M., Haffty B., Xia F. P53-dependent BRCA1 nuclear export controls cellular susceptibility to DNA damage. Cancer Res. 2011, 71:5546-5557.
79. Feng Z., Kachnic L., Zhang J., Powell S.N., Xia F. DNA damage induces p53-dependent BRCA1 nuclear export. J. Biol. Chem. 2004, 279:28574-28584.
80. Aziz K., Nowsheen S., Georgakilas A.G. Nanotechnology in cancer therapy: targeting the inhibition of key DNA repair pathways. Curr. Mol. Med. 2010, 10:626-639.
81. Yang E.S., Wang H., Jiang G., Nowsheen S., Fu A., Hallahan D.E., Xia F. Lithium-mediated protection of hippocampal cells involves enhancement of DNA-PK dependent repair in mice. J. Clin. Invest. 2009, 119:1124-1135.
82. King M.C., Marks J.H., Mandell J.B., The New York Breast Cancer Study Breast and Ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003, 302:643-646.
83. Graeser M.K., Engel C., Rhiem K., Gadzicki D., Bick U., Kast K., Froster U.G., Schlehe B., Bechtold A., Arnold N., Preisler-Adams S., Nestle-Kraemling C., Zaino M., Loeffler M., Kiechle M., Meindl A., Varga D., Schmutzler R.K. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J. Clin. Oncol. 2009, 27:5887-5892.
84. Esteller M., Silva J.M., Dominguez G., Bonilla F., Matias-Guiu X., Lerma E., Bussaglia E., Prat J., Harkes I.C., Repasky E.A., Gabrielson E., Schutte M., Baylin S.B., Herman J.G. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl. Cancer Inst. 2000, 92:564-569.
85. Marsit C.J., Liu M., Nelson H.H., Posner M., Suzuki M., Kelsey K.T. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 2003, 23:1000-1004.
86. Vesuna F., Lisok A., Kimble B., Domek J., Kato Y., van der Groep P., Artemov D., Kowalski J., Carraway H., van Diest P., Raman V. Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-[alpha]. Oncogene 2011.
87. Abell Amy N., Jordan Nicole V., Huang W., Prat A., Midland Alicia A., Johnson Nancy L., Granger Deborah A., Mieczkowski Piotr A., Perou Charles M., Gomez Shawn M., Li L., Johnson Gary L. MAP3K4/CBP-regulated H2B acetylation controls epithelial-mesenchymal transition in trophoblast stem cells. Cell Stem Cell 2011, 8:525-537.
88. Heredia F., Nieto M.A. An epigenetic mark that protects the epithelial phenotype in health and disease. Cell Stem Cell 2011, 8:462-463.
89. Jordan N.V., Johnson G.L., Abell A.N. Tracking the intermediate stages of epithelial-mesenchymal transition in epithelial stem cells and cancer. Cell Cycle 2011, 10:2865-2873.
90. Brock M.V., Hooker C.M., Ota-Machida E., Han Y., Guo M., Ames S., GlÃckner S., Piantadosi S., Gabrielson E., Pridham G., Pelosky K., Belinsky S.A., Yang S.C., Baylin S.B., Herman J.G. DNA methylation markers and early recurrence in Stage I lung cancer. N. Eng. J. Med. 2008, 358:1118-1128.
91. Juergens R.A., Wrangle J., Vendetti F.P., Murphy S.C., Zhao M., Coleman B., Sebree R., Rodgers K., Hooker C.M., Franco N., Lee B., Tsai S., Delgado I.E., Rudek M.A., Belinsky S.A., Herman J.G., Baylin S.B., Brock M.V., Rudin C.M. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discovery 2011, 1:598-607.
92. Cornacchia E., Golbus J., Maybaum J., Strahler J., Hanash S., Richardson B. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J. Immunol. 1988, 140:2197-2200.
93. Yildirim E., Zhang Z., Uz T., Chen C.-q., Manev R., Manev H. Valproate administration to mice increases histone acetylation and 5-lipoxygenase content in the hippocampus. Neurosci. Lett. 2003, 345:141-143.
94. W.M.C.O.C. University, Phase I Study of Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy in Patients With Resectable Esophageal Cancer, ClinicalTrials.gov, NCT01386346, 2012.
95. E. University, Novartis, E. Inc., Re-expression of ER in Triple Negative Breast Cancers, ClinicalTrials.gov, NCT01194908, 2012.
96. N.C. Institute, O.S. University, P.V.M. Center, O.K.C. Institute, Chemoprevention of Prostate Cancer, HDAC Inhibition and DNA Methylation, Clinicaltrails.gov, NCT01265953, 2012.
97. S. AG, Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS), Clinicaltrails.gov, NCT01344707, 2012.